At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Acalabrutinib +1 moredrug
Likely dose
Acalabrutinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated CLL/SLL
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Completed, enrolled 39 participants across 1 site.
Detailed Summary
The main purpose of this research study is to find out if the combination of acalabrutinib and high frequency low dose subcutaneous rituximab is safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartMar 2019
Primary CompletionMay 2023
TodayJul 2026
First PostedDec 27, 2018
Enrollment StartMar 25, 2019
Primary CompletionMay 19, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.5 years ago
Interventions
Acalabrutinibdrug
100 mg by mouth twice a day starting on day 8 of cycle 1
Rituximabdrug
Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.